The MRGPR family of receptors plays a crucial role in immunity and sensory biology. These receptors, expressed on immune cells like mast cells, dendritic cells, and neutrophils, regulate immune and neuroimmune pathways involved in various physiological and pathological states. They are involved in inflammatory conditions, bacterial immunity, and the sensing of environmental exposures such as allergens and irritants. MRGPRs facilitate communication between sensory nerves and immune cells, leading to immune cell activation and the release of pro-inflammatory cytokines. Clinical trials targeting MRGPRs for immune-related disorders are ongoing, suggesting their potential as therapeutic targets. The MRGPR family includes multiple subfamilies with distinct ligand binding properties. MRGPRX2, expressed in mast cells, is involved in skin infections and inflammation, and its activation can lead to mast cell degranulation and adverse drug reactions. The Mrgprb2/MRGPRX2 axis is also critical in the host response to bacterial infections and tick bites. Mast cells, through MRGPRs, contribute to the detection of microbial pathogens and the regulation of immune responses, including the production of antimicrobial peptides and the recruitment of immune cells. In dermatitis and itch, MRGPRs are involved in the neuroimmune axis, with Mrgprb2 playing a key role in non-histaminergic itch. Mast cells express MRGPRs that can be activated by various ligands, including antimicrobial peptides and neuropeptides, leading to the release of mediators that drive inflammatory responses. The Mrgprb2/MRGPRX2 axis is also involved in the pathogenesis of atopic dermatitis and other skin conditions, where mast cell activation contributes to immune cell infiltration and inflammation. In pain, MRGPRs, particularly Mrgprb2, are involved in the sensory perception of inflammatory pain. Mast cells expressing Mrgprb2 can be activated by bacterial products and contribute to pain signaling. The Mrgprb2/MRGPRX2 axis is also implicated in migraine pain, with neuropeptides like PACAP mediating this response. In alcohol withdrawal-induced headache, Mrgprb2 is involved in pain perception through the activation of mast cells. In dendritic cells and neutrophils, Mrgprs are expressed and involved in immune responses. Mrgpra1 is expressed in skin dendritic cells and promotes allergic inflammation. Mrgpr2a/2b on neutrophils are involved in anti-bacterial responses to skin infections. The structure and signaling of MRGPRs involve interactions with G-proteins and β-arrestins, with distinct activation models depending on the ligand. Targeting MRGPRs in clinical settings is being explored for skin diseases and inflammatory conditions. MRGPRX2 is a potential target for treating conditions like atopic dermatitis and chronic urticaria, where mast cell dysregulation plays a role. The expressionThe MRGPR family of receptors plays a crucial role in immunity and sensory biology. These receptors, expressed on immune cells like mast cells, dendritic cells, and neutrophils, regulate immune and neuroimmune pathways involved in various physiological and pathological states. They are involved in inflammatory conditions, bacterial immunity, and the sensing of environmental exposures such as allergens and irritants. MRGPRs facilitate communication between sensory nerves and immune cells, leading to immune cell activation and the release of pro-inflammatory cytokines. Clinical trials targeting MRGPRs for immune-related disorders are ongoing, suggesting their potential as therapeutic targets. The MRGPR family includes multiple subfamilies with distinct ligand binding properties. MRGPRX2, expressed in mast cells, is involved in skin infections and inflammation, and its activation can lead to mast cell degranulation and adverse drug reactions. The Mrgprb2/MRGPRX2 axis is also critical in the host response to bacterial infections and tick bites. Mast cells, through MRGPRs, contribute to the detection of microbial pathogens and the regulation of immune responses, including the production of antimicrobial peptides and the recruitment of immune cells. In dermatitis and itch, MRGPRs are involved in the neuroimmune axis, with Mrgprb2 playing a key role in non-histaminergic itch. Mast cells express MRGPRs that can be activated by various ligands, including antimicrobial peptides and neuropeptides, leading to the release of mediators that drive inflammatory responses. The Mrgprb2/MRGPRX2 axis is also involved in the pathogenesis of atopic dermatitis and other skin conditions, where mast cell activation contributes to immune cell infiltration and inflammation. In pain, MRGPRs, particularly Mrgprb2, are involved in the sensory perception of inflammatory pain. Mast cells expressing Mrgprb2 can be activated by bacterial products and contribute to pain signaling. The Mrgprb2/MRGPRX2 axis is also implicated in migraine pain, with neuropeptides like PACAP mediating this response. In alcohol withdrawal-induced headache, Mrgprb2 is involved in pain perception through the activation of mast cells. In dendritic cells and neutrophils, Mrgprs are expressed and involved in immune responses. Mrgpra1 is expressed in skin dendritic cells and promotes allergic inflammation. Mrgpr2a/2b on neutrophils are involved in anti-bacterial responses to skin infections. The structure and signaling of MRGPRs involve interactions with G-proteins and β-arrestins, with distinct activation models depending on the ligand. Targeting MRGPRs in clinical settings is being explored for skin diseases and inflammatory conditions. MRGPRX2 is a potential target for treating conditions like atopic dermatitis and chronic urticaria, where mast cell dysregulation plays a role. The expression